Prasugrel [Power / Sample Size]

posted by Helmut Homepage – Vienna, Austria, 2012-11-26 14:48 (4961 d 06:00 ago) – Posting: # 9591
Views: 20,654

Dear Madam,

which regulation are you aiming at? Which compound – parent, metabolite(s) – have you measured?
FDA wants to see two metabolites: R-95813 (inactive) and R-138727 (active); BE based on the inactive R-95813.
Following what EMA stated in the Q&A-document on clopidogrel I would expect that they want to see BE based on the parent. Only if you can justify that it is not possible to reliable measure the parent you can go with one of the metabolites – active or inactive (BE GL).

With a ratio of >120% it is very (very!) unlikely that you will be able to show BE in a larger study. Reformulate.

General remark: For the majority of formulations BE in fed state is more difficult to show than in fasted state. It is beyond my intellectual reach why many companies start with the fasted study only to find out that they fail in the fed. Reverse the order and save money.
Send me a pay-check for the tip. :-D

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
281 visitors (0 registered, 281 guests [including 15 identified bots]).
Forum time: 21:48 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5